Omeros (OMER) Net Income towards Common Stockholders (2010 - 2026)

Omeros (OMER) posted Net Income towards Common Stockholders of $4.8 million for Q1 2026, down 26.67% sequentially from $6.6 million in Q4 2025, and up 17.2% YoY from $4.1 million in Q1 2025.

Omeros (OMER) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Omeros has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $4.8 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 17.2% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 90.69% YoY) and the FY2025 annual result came in at $1.5 million, down 94.35% from the prior year.
  • Net Income towards Common Stockholders declined to $4.8 million in Q1 2026 per OMER's latest filing, from $6.6 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $174.8 million in Q4 2022 and troughed at -$9.7 million in Q3 2025.
  • A 5-year average of $18.7 million and a median of $6.6 million in 2025 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 73.05% in 2022, then tumbled 298.2% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at $174.8 million in 2022, then sank by 82.71% to $30.2 million in 2023, then plunged by 82.85% to $5.2 million in 2024, then gained by 26.59% to $6.6 million in 2025, then retreated by 26.67% to $4.8 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $4.8 million, $6.6 million, and -$9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 472.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 930.12
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 Omeros 1.24 Bn 1.24 Bn 27.73 Mn 6.60 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 6.60 Mn
Mar 31, 2026 4.81 Mn
Dec 31, 2025 6.56 Mn
Sep 30, 2025 -9.67 Mn
Jun 30, 2025 466,000.00
Mar 31, 2025 4.11 Mn
Dec 31, 2024 5.18 Mn
Sep 30, 2024 4.88 Mn
Jun 30, 2024 9.08 Mn
Mar 31, 2024 6.67 Mn
Dec 31, 2023 30.22 Mn
Sep 30, 2023 13.91 Mn
Jun 30, 2023 7.00 Mn
Mar 31, 2023 5.98 Mn
Dec 31, 2022 174.78 Mn
Sep 30, 2022 37.34 Mn
Jun 30, 2022 10.85 Mn
Mar 31, 2022 6.48 Mn
Dec 31, 2021 328.94 Mn
Sep 30, 2021 21.58 Mn